Abaxis (ABAX) Tops Q3 EPS by 2c, Revenue Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2016, Declares Quarterly Cash Dividend
January 28, 2016 4:01 PM ESTUNION CITY, Calif., Jan. 28, 2016 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today reported financial results for the third fiscal quarter ended December 31, 2015.
Third quarter highlights include:
Total medical and veterinary reagent disc sales of 2.3 million units, up 12% over last year's comparable quarter. International revenues of $11.8 million, up 12% over last year's comparable quarter. Gross profit from continuing operations of $29.6 million, up 3% over last year's comparable quarter. Income from... More